Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedMay 7, 2014Fluoxetine CapsulesChemical Contamination: The recalling firm received notice that their supplier is recalling capsules due to complaints of capsules having an unusual odor.Legacy Pharmaceutical Packaging · D-1279-2014Class ITerminatedMay 7, 2014Lidocaine HCl InjectionPresence of Particulate Matter- Confimed customer complaint of particulates embedded in glass container and in contact with product solution.Hospira Inc. · D-1278-2014Class ITerminatedMay 7, 2014Adipotrim XTMarketed Without an Approved NDA/ANDA: FDA lab results found undeclared API Fluoxetine in this dietary supplement.Deseo Rebajar · D-1277-2014Class ITerminatedMay 7, 2014Dianeal PD-2 Peritoneal Dialysis Solution with 1.5% DextroseNon-Sterility: Complaints of leaks and particulate matter identified as mold in the solution bag and the overpouch.Baxter Healthcare Corp. · D-1276-2014Class ITerminatedMay 7, 2014Hyperlyte CRPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1275-2014Class ITerminatedMay 7, 2014ProcalAminePresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1274-2014Class ITerminatedMay 7, 2014TrophAminePresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1273-2014Class ITerminatedMay 7, 201415% Amino Acids Injection PBP GlassPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1272-2014Class ITerminatedMay 7, 20146.9% FreAmine HBCPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1271-2014Class ITerminatedMay 7, 20140.9 % Sodium Chloride Injection USPPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1270-2014Class ITerminatedMay 7, 2014Cefazolin for Injection USP and Dextrose Injection USPPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1269-2014Class ITerminatedMay 7, 2014Cefazolin for Injection USP and Dextrose Injections USPPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1268-2014Class ITerminatedMay 7, 2014Cefepime for Injections USP and Dextrose Injection USPPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1267-2014Class ITerminatedMay 7, 2014Ceftriaxone for Injection and Dextrose InjectionPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1266-2014Class ITerminatedMay 7, 20140.9 % Sodium Chloride Injection USP in PAB 50 mL partial fill in 100 mL PAB ContainerPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1265-2014Class ITerminatedMay 7, 2014Cefoxitin for Injection and Dextrose InjectionPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1264-2014Class ITerminatedMay 7, 2014Human Chorionic GonadotropinLabeling: Label Error on Declared Strength; Firm states that erroneous potency information was found on the label.Medisca Inc. · D-1263-2014Class IITerminatedMay 7, 2014SevofluraneFailed pH Specifications: product was too acidic.Piramal Critical Care, Inc. · D-1262-2014Class IITerminatedMay 7, 2014Polidocanol 3% SolutionPresence of Particulate MatterJohn W Hollis Inc · D-1260-2014Class IIITerminatedMay 7, 2014Polidocanol 1% SolutionLabeling: Incorrect Expiration Date; Expiration date is earlier than listed on vial.John W Hollis Inc · D-1259-2014Class IIITerminatedMay 7, 2014Papaverine 60 mgLabeling: Incorrect Expiration Date; Expiration date is earlier than listed on vial.John W Hollis Inc · D-1258-2014Class IITerminatedMay 7, 2014Phosphatidylcholine Solution for InjectionLabeling: Incorrect Expiration Date; Expiration date is earlier than listed on vial.John W Hollis Inc · D-1257-2014Class IITerminatedApr 30, 2014Potassium Chloride for Inj. ConcentratePresence of Particulate; red and black particulate within the solution and embedded within the plastic vial identified as iron oxideHospira Inc. · D-1261-2014Class IITerminatedApr 30, 2014Non-Drowsy 24 Hour Formula Allergy Relief and Nasal DecongestantDefective Container: An unacceptable level of blister defects have been identified in Loratadine and Pseudoephedrine Sulfate Extended Release Tablets, 10 mg/240 mg.Ohm Laboratories, Inc. · D-1256-2014Class IIITerminatedApr 30, 2014Oxandrolone TabletsLabeling: Missing Label; Three cases of product (total of 36 bottles) were packaged without the primary label on the bottle. The cases were, however, packaged in the...Upsher Smith Laboratories, Inc. · D-1255-2014Class IIITerminatedApr 30, 2014Day Time Cold & FluSubpotent Drug: Phenylephrine component is subpotent.P&L Developments, LLC · D-1254-2014Class IITerminatedApr 30, 2014Tikosyn¿Presence of Foriegn Tablets/Capsules: A single Tikosyn¿ (dofetilide) 250 mcg capsule was discovered in one bottle of Tikosyn¿ (dofetilide) 500 mcg (0.5 mg).Pfizer Inc. · D-1253-2014Class ITerminatedApr 30, 2014GlycopyrrolateNon-Sterility: One lot of Glycopyrrolate solution for injection was found to be contaminated with Bacillus thuringiensis.Brookfield Prescription Center Inc · D-1252-2014Class ITerminatedApr 30, 2014VPRIV¿ (velaglucerase alfa for injection)Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.Shire Human Genetic Therapies, Inc. · D-1251-2014Class ITerminatedApr 30, 2014XIYOUJI QINGZHI CAPSULEMarketed without an Approved NDA/ANDA: Products found to contain undeclared sibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these...Dolphin Intertrade Corporation · D-1250-2014Class ITerminatedApr 30, 2014JaDera, 100% Natural Weight Loss SupplementMarketed without an Approved NDA/ANDA: Products found to contain undeclared sibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these...Dolphin Intertrade Corporation · D-1249-2014Class ITerminatedApr 30, 2014RezzRX capsulesMarketed Without an Approved NDA/ANDA: Fossil Fuel Products, is recalling RezzRX due to undeclared hydroxylthiohomosildenafil and aminotadalafil.Fossil Fuel Products, LLC · D-1248-2014Class IIITerminatedApr 30, 2014Nicorette Lozenge and NicoDerm CQFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1247-2014Class IIITerminatedApr 30, 2014NicoretteFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1246-2014Class IIITerminatedApr 30, 2014NicoretteFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1245-2014Class IIITerminatedApr 30, 2014Nicorette LozengeFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1244-2014Class IIITerminatedApr 30, 2014Nicotine polacrilex lozengeFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1243-2014Class IIITerminatedApr 30, 2014Nicotine polacrilex lozengeFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1242-2014Class IIITerminatedApr 30, 2014Nicotine polacrilex lozengeFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1241-2014Class IIITerminatedApr 30, 2014Nicotine polacrilex lozengeFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1240-2014